No similar products found.
Description
Alkacel 5 mg Tablet contains Melphalan, an oral chemotherapy medicine used to treat multiple myeloma and certain ovarian cancers. It works by slowing the growth of cancer cells under oncologist supervision.
Benefits
-
Slows or stops cancer cell multiplication
-
Helps reduce tumor burden
-
Improves treatment outcomes in multiple myeloma
-
Effective oral chemotherapy option in certain cancers
Indications and Usage
Alkacel 5 mg Tablet is indicated for:
-
Multiple Myeloma
-
Advanced Ovarian Cancer
-
May be used as part of conditioning therapy before stem cell transplant (as clinically advised)
Treatment should be initiated and supervised by an oncologist.
How it Works
Melphalan is an alkylating chemotherapy agent that binds to DNA inside cancer cells, preventing replication and triggering cell death. This helps slow or stop tumor growth in susceptible cancers.
Dosage & Administration
-
Dose is individualized based on cancer type, body weight, and treatment plan
-
Swallow tablets whole with water — do not crush or chew
-
Can be taken with or without food, as advised
-
Do not skip, double, or stop dosing without medical guidance
-
Frequent blood tests are required to monitor blood counts and organ function
Use only under oncologist direction.
Side Effects
Common side effects:
-
Nausea or vomiting
-
Fatigue or weakness
-
Mouth sores
-
Hair thinning
-
Low blood cell counts (anemia, neutropenia, thrombocytopenia)
Serious side effects (seek urgent care):
-
Severe infection or fever
-
Unusual bleeding or bruising
-
Allergic reactions
-
Liver or kidney dysfunction
Warning and Precaution
-
Not recommended during pregnancy or breastfeeding
-
May cause severe bone marrow suppression—regular monitoring required
-
Inform doctor if you have kidney or liver disease
-
Increased infection and bleeding risk — avoid contact with sick individuals
-
Avoid live vaccines during treatment
-
Report persistent fever, bleeding, or breathing difficulty immediately
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.